[The PCPT study: the viewpoint of an urologist involved].
The PCPT study investigating the possibility of decreasing the incidence of prostate cancer by daily administration of 5 mg of finasteride for 7 years appears to be a major clinical study in the management of this disease. Recently published in the New England Journal of Medicine, it makes difficult reading. The current article aims to demonstrate the main methodological characteristics of this study, to describe the most significant results and to discuss its clinical applications in daily urological practice.
Fourcade
R O
RO
Service d'urologie, centre hospitalier, 2, boulevard de Verdun, 89000 Auxerre, France. rfourcade@ch-auxerre.fr
D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D013997:Time Factors; D014572:Urology
D018120:Finasteride; D042944:Cholestenone 5 alpha-Reductase